نتائج البحث - "Caroline Robert"

1

Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)

المساهمون: University of Zurich

مصطلحات موضوعية: Male, 0301 basic medicine, Cancer Research, Skin Neoplasms, Health-related quality of life, Medizin, Hospitalisation rate, chemistry.chemical_compound, 0302 clinical medicine, Quality of life, Antineoplastic Combined Chemotherapy Protocols, Vemurafenib, Melanoma, Aged, 80 and over, Sulfonamides, 10177 Dermatology Clinic, Binimetinib, Middle Aged, Progression-Free Survival, humanities, Oncology, Tolerability, 030220 oncology & carcinogenesis, Female, Open label, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, 610 Medicine & health, BRAF(V600E−K) mutant Melanoma, Young Adult, 03 medical and health sciences, BRAF/MEK inhibitors Combination, Internal medicine, medicine, Humans, In patient, Encorafenib plus binimetinib, Aged, business.industry, Repeated measures design, medicine.disease, 030104 developmental biology, chemistry, Mutation, Quality of Life, Benzimidazoles, Carbamates, business

وصف الملف: 898_Gogas_H._et_al._Quality_of_life_in_patients_with_BRAF_mutant_melanoma_receiving_the_combination_encorafenib_plus_binimetinib_EJC_2021.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00b598bc6b0d5210f8adf8a69fd7b47bTest
https://www.zora.uzh.ch/id/eprint/203982Test/

2

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

المساهمون: University of Zurich, Dummer, Reinhard

المصدر: The Lancet Oncology. 19:1315-1327

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Skin Neoplasms, Time Factors, Medizin, Phases of clinical research, Gene mutation, chemistry.chemical_compound, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Vemurafenib, Melanoma, Aged, 80 and over, Trametinib, Sulfonamides, 10177 Dermatology Clinic, Binimetinib, Middle Aged, Progression-Free Survival, Phenotype, Tolerability, 030220 oncology & carcinogenesis, Disease Progression, Female, 2730 Oncology, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, 610 Medicine & health, Young Adult, 03 medical and health sciences, Internal medicine, Biomarkers, Tumor, medicine, Humans, Genetic Predisposition to Disease, Progression-free survival, Protein Kinase Inhibitors, Aged, Performance status, business.industry, 030104 developmental biology, chemistry, Mutation, Benzimidazoles, Carbamates, business

وصف الملف: 775_Dummer_R._et_al._Overall_survival_in_patients_with_BRAF-mutant_melanoma_receiving_encorafenib_plus_Lancet_Oncol._2018.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8bb4f4dc2694f231c2c21cb1932e261Test
https://doi.org/10.1016/s1470-2045Test(18)30497-2

3

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

المؤلفون: Shannon Marshall, Alain Algazi, Sunandana Chandra, Caroline Robert, Nancy Mueller, Leonel Hernandez-Aya, Wilson H. Miller, Jose Lutzky, Marcus O. Butler, Michael D. Gordon, Paolo A. Ascierto, Antoni Ribas, Bruno Delafont, Katie M. Campbell, Donald P. Lawrence

المصدر: Nature communications, vol 11, iss 1
Nature Communications
Nature Communications, Vol 11, Iss 1, Pp 1-10 (2020)

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Durvalumab, Skin Neoplasms, General Physics and Astronomy, B7-H1 Antigen, Cohort Studies, 0302 clinical medicine, Oximes, Antineoplastic Combined Chemotherapy Protocols, Monoclonal, 80 and over, Melanoma, Cancer, Trametinib, Aged, 80 and over, Multidisciplinary, MEK inhibitor, Imidazoles, Antibodies, Monoclonal, Middle Aged, Progression-Free Survival, Tolerability, 030220 oncology & carcinogenesis, 6.1 Pharmaceuticals, Cohort, Female, Mitogen-Activated Protein Kinases, medicine.drug, Cohort study, Diarrhea, Proto-Oncogene Proteins B-raf, Adult, medicine.medical_specialty, Pyridones, Science, Immunology, Clinical Trials and Supportive Activities, Pyrimidinones, Article, General Biochemistry, Genetics and Molecular Biology, Antibodies, 03 medical and health sciences, Young Adult, Clinical Research, Internal medicine, medicine, Humans, Author Correction, neoplasms, Aged, business.industry, Evaluation of treatments and therapeutic interventions, Dabrafenib, General Chemistry, Exanthema, medicine.disease, 030104 developmental biology, Mutation, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::214f5a164c72be16363987dcb81eb292Test
https://escholarship.org/uc/item/344192vkTest

4

Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma : safety run-in and biomarker cohorts of COMBI-i

المساهمون: University of Zurich, Dummer, Reinhard

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Skin Neoplasms, Medizin, Cohort Studies, 0302 clinical medicine, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Oximes, Clinical endpoint, Neoplasm Metastasis, Immune Checkpoint Inhibitors, Melanoma, Trametinib, MEK inhibitor, Imidazoles, 10177 Dermatology Clinic, General Medicine, Middle Aged, MAP Kinase Kinase Kinases, Treatment Outcome, 030220 oncology & carcinogenesis, Disease Progression, Biomarker (medicine), Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, Mutation, Missense, 610 Medicine & health, Genetics and Molecular Biology, Pyrimidinones, Antibodies, Monoclonal, Humanized, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Young Adult, 1300 General Biochemistry, Genetics and Molecular Biology, Internal medicine, medicine, Biomarkers, Tumor, Humans, Protein Kinase Inhibitors, Aged, business.industry, Dabrafenib, medicine.disease, Clinical trial, Regimen, 030104 developmental biology, General Biochemistry, business

وصف الملف: 870_Dummer_R._et_al._Combined_PD-1,_BRAF_and_MEK_inhibition_in_advanced_BRAF-mutant_melanoma_Nature_Medicine_2020.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b17ee96d80a3281cdd7448c58c9110fTest
https://www.ncbi.nlm.nih.gov/pubmed/33020648Test

5

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

المصدر: The Lancet Oncology. 19:603-615

مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, 0301 basic medicine, Oncology, medicine.medical_specialty, Skin Neoplasms, Time Factors, Phases of clinical research, Young Adult, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, medicine, Humans, Molecular Targeted Therapy, Progression-free survival, Vemurafenib, Melanoma, Protein Kinase Inhibitors, Aged, Aged, 80 and over, Sulfonamides, Performance status, business.industry, MEK inhibitor, Binimetinib, Middle Aged, medicine.disease, Progression-Free Survival, 030104 developmental biology, Tolerability, chemistry, 030220 oncology & carcinogenesis, Mutation, Benzimidazoles, Female, Carbamates, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39b9a8d731aee37b91ba57a2467a28bbTest
https://doi.org/10.1016/s1470-2045Test(18)30142-6

6

Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated Melanoma

المساهمون: University of Zurich, Long, Georgina V

المصدر: New England Journal of Medicine. 377:1813-1823

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Skin Neoplasms, Medizin, 2700 General Medicine, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, Clinical endpoint, Melanoma, Aged, 80 and over, Trametinib, MEK inhibitor, Imidazoles, 10177 Dermatology Clinic, General Medicine, Middle Aged, 030220 oncology & carcinogenesis, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Adolescent, Combination therapy, Pyridones, 610 Medicine & health, Pyrimidinones, Young Adult, 03 medical and health sciences, Adjuvants, Immunologic, Double-Blind Method, Internal medicine, medicine, Humans, Survival analysis, Aged, Neoplasm Staging, business.industry, Dabrafenib, medicine.disease, Survival Analysis, Surgery, Clinical trial, 030104 developmental biology, Mutation, Neoplasm Recurrence, Local, business

وصف الملف: 720_Long_GV._et_al._Adjuvant_Dabrafenib_plus_Trametinib_in_Stage_III_NEJM_2017.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c20521edecf000680510735bacb9ee32Test
https://doi.org/10.1056/nejmoa1708539Test

7

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma

المؤلفون: Mohammed M. Milhem, Peter Mohr, Paul Nathan, Piotr Rutkowski, Anthony D'Amelio, Peter Hersey, Felix Kiecker, Jochen Utikal, Lev V. Demidov, Caroline Robert, Reinhard Dummer, Claus Garbe, Dirk Schadendorf, Jessica C. Hassel, Bijoyesh Mookerjee, James Larkin, Keith T. Flaherty

المساهمون: Department of Dermatology (CHU Besançon), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), N.N. Blokhin Russian Cancer Research Center, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Novartis Pharmaceutical Corporation, University of Zurich, Robert, Caroline

المصدر: European Journal of Cancer
European Journal of Cancer, Elsevier, 2019, 109, pp.61-69. ⟨10.1016/j.ejca.2018.12.015⟩

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, Time Factors, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Medizin, Phases of clinical research, Targeted therapy, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, 1306 Cancer Research, Melanoma, Trametinib, Aged, 80 and over, Brain Neoplasms, MEK inhibitor, Hazard ratio, 10177 Dermatology Clinic, Middle Aged, Prognosis, 3. Good health, Dacarbazine, Survival Rate, 030220 oncology & carcinogenesis, 2730 Oncology, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Paclitaxel, Pyridones, 610 Medicine & health, Pyrimidinones, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, Adverse effect, Aged, Chemotherapy, business.industry, 030104 developmental biology, Mutation, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28197cc98bbc5b4b985accfda8ddbdbdTest
https://pubmed.ncbi.nlm.nih.gov/30690294Test

8

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma

المساهمون: University of Zurich, Long, Georgina V

المصدر: Journal of Clinical Oncology
J Clin Oncol

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, Internationality, Skin Neoplasms, Time Factors, Medizin, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, Clinical endpoint, 1306 Cancer Research, Stage (cooking), Melanoma, Trametinib, Hazard ratio, Age Factors, Imidazoles, 10177 Dermatology Clinic, Middle Aged, Treatment Outcome, 030220 oncology & carcinogenesis, Female, 2730 Oncology, Rapid Communication, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, 610 Medicine & health, Pyrimidinones, Placebo, Disease-Free Survival, Drug Administration Schedule, 03 medical and health sciences, Sex Factors, Adjuvants, Immunologic, Double-Blind Method, Internal medicine, Correspondence, medicine, Humans, Dose-Response Relationship, Drug, business.industry, Cancer, Dabrafenib, medicine.disease, Clinical trial, 030104 developmental biology, business, Follow-Up Studies

وصف الملف: 767_Hauschild_A._et_al._Longer_follow-up_confirms_relapse-free_survival_benefit_with_adjuvant_dabrafenib_plus_trametinib_in_patients_JCO_2018.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00393631f41ac7c8491c0de2c7f007a8Test
https://doi.org/10.5167/uzh-158265Test

9

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma

المساهمون: University of Zurich, Hamid, Omid

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, Time Factors, medicine.medical_treatment, Medizin, Phases of clinical research, Pembrolizumab, Kaplan-Meier Estimate, 0302 clinical medicine, Antineoplastic Agents, Immunological, 1306 Cancer Research, Melanoma, Aged, 80 and over, education.field_of_study, Cross-Over Studies, Drug Substitution, Hazard ratio, 10177 Dermatology Clinic, Middle Aged, MAP Kinase Kinase Kinases, Treatment Outcome, 030220 oncology & carcinogenesis, Disease Progression, 2730 Oncology, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Adolescent, Population, Ipilimumab, 610 Medicine & health, Antibodies, Monoclonal, Humanized, Disease-Free Survival, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, education, Protein Kinase Inhibitors, Aged, Chemotherapy, business.industry, medicine.disease, Confidence interval, Surgery, 030104 developmental biology, Drug Resistance, Neoplasm, Mutation, business

وصف الملف: 721_Hamid_O._et_al._Final_analysis_of_randomised_trial_comparing_pembrolizumab_versus_Eur_J_Cancer_2017.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab24a3779538f584d0432f320113cbb5Test
https://www.ncbi.nlm.nih.gov/pubmed/28961465Test

10

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

المصدر: Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid

مصطلحات موضوعية: 0301 basic medicine, Oncology, Adult, Male, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Fever, Pyridones, Population, Phases of clinical research, Pyrimidinones, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, medicine, Humans, Prospective Studies, education, Prospective cohort study, neoplasms, Melanoma, Aged, Trametinib, Aged, 80 and over, education.field_of_study, Performance status, business.industry, Brain Neoplasms, Headache, Imidazoles, Dabrafenib, Stroke Volume, Middle Aged, medicine.disease, Magnetic Resonance Imaging, Surgery, 030104 developmental biology, 030220 oncology & carcinogenesis, Cohort, Mutation, Female, business, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75ca2250695a09ca77827d7a14819fb8Test
https://hdl.handle.net/20.500.12530/31583Test

تنقيح النتائج